Eton Pharmaceuticals Inc (ETON)
7.00
+0.09
(+1.30%)
USD |
NASDAQ |
Oct 04, 16:00
6.97
-0.03
(-0.43%)
After-Hours: 20:00
Eton Pharmaceuticals SG&A Expense (Annual): 18.93M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 18.93M |
| December 31, 2022 | 18.58M |
| December 31, 2021 | 14.26M |
| Date | Value |
|---|---|
| December 31, 2020 | 12.61M |
| December 31, 2019 | 7.552M |
| December 31, 2018 | 4.694M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.552M
Minimum
2019
18.93M
Maximum
2023
14.39M
Average
14.26M
Median
2021
SG&A Expense (Annual) Benchmarks
| Biomarin Pharmaceutical Inc | 937.30M |
| Integra Lifesciences Holdings Corp | 656.64M |
| Elutia Inc | 27.19M |
| Immuneering Corp | 16.76M |
| Journey Medical Corp | 43.91M |